BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 22907845)

  • 1. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
    Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
    Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.
    Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K
    Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function.
    Tao LY; Liang YJ; Wang F; Chen LM; Yan YY; Dai CL; Fu LW
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):961-9. PubMed ID: 19255759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal effect of Raf-1/Mdr-1 siRNAs co-transfection on multidrug resistance in KBv200 cell line.
    Dong Y; Shao S; Hu J; Yang P
    Oral Oncol; 2009 Nov; 45(11):991-7. PubMed ID: 19631573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line.
    Guan J; Chen XP; Zhu H; Luo SF; Cao B; Ding L
    World J Gastroenterol; 2004 Dec; 10(23):3522-7. PubMed ID: 15526378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance of hepatocellular carcinoma].
    Zhu H; Chen XP; Luo SF; Guan J; Zhang WG; Zhang BX; Mao CP
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(13):917-20. PubMed ID: 17953842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
    Ochi N; Takigawa N; Harada D; Yasugi M; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
    Exp Cell Res; 2014 Mar; 322(1):168-77. PubMed ID: 24440771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance and reversal of MDR1/P-gp in pancreatic cancer chemotherapy].
    Guo JC; Zhao YP; Liao Q; Zhu Y
    Zhonghua Wai Ke Za Zhi; 2007 Nov; 45(21):1488-90. PubMed ID: 18275717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.
    Ma SL; Hu YP; Wang F; Huang ZC; Chen YF; Wang XK; Fu LW
    Mol Med; 2014 Sep; 20(1):390-9. PubMed ID: 25105301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
    World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
    Kitazaki T; Oka M; Nakamura Y; Tsurutani J; Doi S; Yasunaga M; Takemura M; Yabuuchi H; Soda H; Kohno S
    Lung Cancer; 2005 Sep; 49(3):337-43. PubMed ID: 15955594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
    Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
    Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
    Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
    Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.
    Yan F; Wang XM; Liu ZC; Pan C; Yuan SB; Ma QM
    Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):287-95. PubMed ID: 20525557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.